Page 1 | Search Results | Blood | American Society of Hematology

1-17 of 17

Sort by

Sort Order Select

Journal Articles

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Karl J. Aichberger, Karoline V. Gleixner, Irina Mirkina, Sabine Cerny-Reiterer, Barbara Peter, Veronika Ferenc, Michael Kneidinger, Christian Baumgartner, Matthias Mayerhofer, Alexander Gruze, Winfried F. Pickl, Christian Sillaber, Peter Valent

Blood (2009) 114 (26): 5342–5351.

https://doi.org/10.1182/blood-2008-08-175190

Published: 2009

Journal Articles

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Karoline Veronika Gleixner, MD, Lily L Remsing Rix, Christian Baumgartner, Uwe Rix, Alexander Gruze, Renata Anna Meyer, M.D., Winfried F. Pickl, MD, Christian Sillaber, Martin Augustin, Jeff Till, Giulio Superti-Furga, Peter Valent, MD

Blood (2008) 112 (11): 3195.

https://doi.org/10.1182/blood.V112.11.3195.3195

Published: 2008

Journal Articles

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Renata A. Meyer, MD, Harald Herrmann, MD, Karoline V. Gleixner, MD, Alexander Gruze, Sabine Cerny-Reiterer, MD, Rainer Hubmann, PhD, Medhat Shehata, MD, Matthias Mayerhofer, MD, Wolfgang R. Sperr, MD, Winfried F. Pickl, MD, Junia V. Melo, PhD, Gahininath Y. Bharate, Ulrich Jäger, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2008) 112 (11): 1616.

https://doi.org/10.1182/blood.V112.11.1616.1616

Published: 2008

Journal Articles

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Barbara Peter, MVM, Karl J. Aichberger, MD, Karoline V. Gleixner, MD, Veronika Ferenc, MD, Alexander Gruze, Winfried F. Pickl, MD, Michael Willmann, DVM, Peter Valent, MD

Blood (2008) 112 (11): 861.

https://doi.org/10.1182/blood.V112.11.861.861

Published: 2008

Journal Articles

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Karoline V. Gleixner, MD, Matthias Mayerhofer, M.D., Uwe Rix, Ph.D., Gregor Hoermann, Alexander Gruze, Maria-Theresa Krauth, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Giulio Superti-Furga, Ph.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1541.

https://doi.org/10.1182/blood.V110.11.1541.1541

Published: 2007

Journal Articles

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

Christian Baumgartner, MD, Karoline V. Gleixner, M.D., Alexander Gruze, Puchit Samorapoompichit, M.D., Harald Esterbauer, M.D, Winfried F. Pickl, M.D, Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3559.

https://doi.org/10.1182/blood.V110.11.3559.3559

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

Veronika Ferenc, MD, Karoline V. Gleixner, M.D., Alexander Gruze, M.D., Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 3554.

https://doi.org/10.1182/blood.V110.11.3554.3554

Published: 2007

Journal Articles

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Karoline V. Gleixner, MD, Veronika Ferenc, M.D., Alexander Gruze, Michael Kneidinger, M.D., Christian Baumgartner, M.D., Matthias Mayerhofer, M.D., Winfried F. Pickl, M.D., Christian Sillaber, M.D., Peter Valent, M.D.

Blood (2007) 110 (11): 1046.

https://doi.org/10.1182/blood.V110.11.1046.1046

Published: 2007

Journal Articles

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Rudin Kondo, Karoline V. Gleixner, Matthias Mayerhofer, Anja Vales, Alexander Gruze, Puchit Samorapoompichit, Khaled Greish, Maria-Theresa Krauth, Karl J. Aichberger, Winfried F. Pickl, Harald Esterbauer, Christian Sillaber, Hiroshi Maeda, Peter Valent

Blood (2007) 110 (2): 661–669.

https://doi.org/10.1182/blood-2006-10-054411

Published: 2007

Includes: Supplemental data

Journal Articles

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Karoline V. Gleixner, MD, Mayerhofer Matthias, MD, Anja Vales, MD, Alexander Gruze, Michael Kneidinger, MD, Gregor Hoermann, Maria T. Krauth, MD, Rudin Kondo, MD, Karoline Sonneck, MD, Puchit Samorapoompichit, MD, Eva Lackner, MD, Khaled Greish, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Christoph C. Zielinski, MD, Hiroshi Maeda, MD, Peter Valent, MD

Blood (2006) 108 (11): 4323.

https://doi.org/10.1182/blood.V108.11.4323.4323

Published: 2006

Journal Articles

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Karl J. Aichberger, Matthias Mayerhofer, Karoline V. Gleixner, Maria-Theresa Krauth, Alexander Gruze, Winfried F. Pickl, Volker Wacheck, Edgar Selzer, Leonhard Müllauer, Hermine Agis, Christian Sillaber, Peter Valent

Blood (2006) 109 (7): 3031–3041.

https://doi.org/10.1182/blood-2006-07-032714

Published: 2006

Journal Articles

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karoline Sonneck, MD, Alexander Gruze, Puchit Samorapoompichit, MD, Karl J. Aichberger, MD, Francis Y. Lee, PhD, Paul W. Manley, PhD, Doriano Fabbro, PhD, Winfried F. Pickl, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 526.

https://doi.org/10.1182/blood.V108.11.526.526

Published: 2006

Journal Articles

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

Michael Kneidinger, MD, Karoline V. Gleixner, md, Rudin Kondo, md, Puchit Samorapoompichit, md, Anja Vales, md, Maria T. Krauth, md, Matthias Mayerhofer, md, Alexander Gruze, Winfried F. Pickl, md, Khaled Greish, Alexandra Boehm, md, Wolfgang R. Sperr, md, Hiroshi Maeda, md, phd, Peter Valent, md

Blood (2006) 108 (11): 1901.

https://doi.org/10.1182/blood.V108.11.1901.1901

Published: 2006

Journal Articles

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

Karl J. Aichberger, MD, PhD, Matthias Mayerhofer, MD, Karoline V. Gleixner, MD, Maria-Theresa Krauth, MD, Alexander Gruze, Winfried F. Pickl, MD, Volker Wacheck, MD, Edgar Selzer, MD, Christian Sillaber, MD, Peter Valent, MD

Blood (2006) 108 (11): 1437.

https://doi.org/10.1182/blood.V108.11.1437.1437

Published: 2006

Journal Articles

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Karoline V. Gleixner, Matthias Mayerhofer, Karl J. Aichberger, Sophia Derdak, Karoline Sonneck, Alexandra Böhm, Alexander Gruze, Puchit Samorapoompichit, Paul W. Manley, Doriano Fabbro, Winfried F. Pickl, Christian Sillaber, Peter Valent

Blood (2006) 107 (2): 752–759.

https://doi.org/10.1182/blood-2005-07-3022

Published: 2006

Journal Articles

Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).

Rudin Kondo, MD, Matthias Mayerhofer, MD, Karoline Gleixner, MD, Anja Vales, MD, Maria-Theresa Krauth, MD, Sophia Derdak, MD, Alexander Gruze, Winfried Pickl, MD, Christian Sillaber, MD, Khaled Greish, MD, Hiroshi Maeda, MD, PhD, Peter Valent, MD

Blood (2005) 106 (11): 3521.

https://doi.org/10.1182/blood.V106.11.3521.3521

Published: 2005

Journal Articles

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Karoline V. Gleixner, MD, Matthias Mayerhofer, MD, Karl J. Aichberger, MD, Sophia Derdak, PhD, Karoline Sonneck, MD, Alexandra Boehm, MD, Puchit Samorapoompichit, MD, Alexander Gruze, Winfried Pickl, Paul Manley, Doriano Fabbro, Christian Sillaber, Peter Valent

Blood (2005) 106 (11): 3523.

https://doi.org/10.1182/blood.V106.11.3523.3523

Published: 2005

NARROW

Identification of proapoptotic Bim as a tumor suppressor in neoplastic mast cells: role of KIT D816V and effects of various targeted drugs

Effects of Bosutinib (SKI-606) in CML: Kinase Target Profile, Effects on BCR/ABL Mutants, and Synergism with Dasatinib in T315I+ Cells

Identification of Heat Shock Protein 32 (Hsp32) as a Novel Target in Acute Lymphoblastic Leukemia (ALL).

Effects of the Mcl-1/Bcl-2 Inhibitor GX015-070 (Obatoclax ® ) on Growth and Viability of Canine and Human Neoplastic Mast Cells

Delineation of a KIT-Independent Oncogenic Pathway in Neoplastic Mast Cells That Involves Lyn and Btk, and Can Be Disrupted by the KIT/Lyn/Btk-Targeting Drug Dasatinib

Dasatinib Inhibits the Growth of Neoplastic Human Eosinophils (EOL-1) through Targeting of FIP1L1-PDGFRα.

The Plk-1 Inhibitor BI 2536 Counteracts the Growth of Neoplastic Mast Cells and Synergizes with the KIT D816V-Targeting Drug Midostaurin (PKC412) in Producing Growth-Inhibition.

The Plk-1 Inhibitor BI 2536 Counteracts Proliferation and Viability of CML Cells and Synergizes with Imatinib and Nilotinib (AMN107) in Producing Growth Inhibition.

Identification of heat shock protein 32 (Hsp32) as a novel survival factor and therapeutic target in neoplastic mast cells

Targeting of Heat Shock Protein 32 (Hsp32) in Neoplastic Cells by Styrene Maleic Acid Zinc Protoporphyrin (SMA-ZnPP) Is Associated with Reduced Growth and Induction of Apoptosis.

Identification of MCL1 as a novel target in neoplastic mast cells in systemic mastocytosis: inhibition of mast cell survival by MCL1 antisense oligonucleotides and synergism with PKC412

Synergistic Growth-Inhibitory Effects of Two Tyrosine Kinase Inhibitors, Dasatinib and PKC412, on Neoplastic Mast Cells Expressing the D816V-Mutated Oncogenic Variant of KIT.

Heme Oxygenase-1 (HO-1)/Heat Shock Protein 32 (Hsp32) as a Novel Survival Factor and Target in AML.

The KIT D816V-Targeting Drug PKC412 Induces Re-Expression of Bim and Synergizes with Mcl-1 Antisense Oligonucleotides in Producing Growth Inhibition in Neoplastic Human Mast Cells.

PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of KIT: comparison with AMN107, imatinib, and cladribine (2CdA) and evaluation of cooperative drug effects

Heme Oxygenase-1 (HO-1): A Novel KIT D816V-Dependent Target in Neoplastic Human Mast Cells (HMC-1).

PKC412 Inhibits In Vitro Growth of Neoplastic Mast Cells Expressing the D816V-Mutated Variant of KIT: Comparison with AMN107 and Imatinib, and Evaluation of Drug-Interactions.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only